Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.

BMC Cancer · 2020 · PMC7368985 · PMID 32684154

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The single-locus survival signature for TAM is also significantly enriched at the 7-month time point in the T47D RA experiment ( p = 0.0032), but not for ER+/HER2- despite an increasing trend in the proportion of CpGs contributing to enrichment in the same direction (‘up’) over time (Table 4 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.